Dopamine Transporter Loss in 6-OHDA Parkinson's Model Is Unmet by Parallel Reduction in Dopamine Uptake

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Chotibut, Tanya ^a   Apple, Deana M ^a   Jefferis, Rebecca ^a   Salvatore, Michael F ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; NORADRENALIN; NORADRENALIN TRANSPORTER; OXIDOPAMINE; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; ENZYME INHIBITION; MALE; NONHUMAN; PARKINSON DISEASE; PROTEIN DEPLETION; RAT; REGULATORY MECHANISM;

ANIMALS; BIOLOGICAL TRANSPORT; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; LEVODOPA; MALE; NEOSTRIATUM; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SYNAPSES; SYNAPTOSOMES; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 84871593657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052322     Document Type: Article

References (80)

1. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, et al. (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. 95: 4029-4034.
2. Jaber M, Dumartin B, Sagne C, Haycock JW, Roubert C, et al. (1999) Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur J Neurosci 11: 3499-3511.
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurological Sci. 20; 415-455.
4. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, et al. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned Macaque model of Parkinson's disease. J. Neurosci. 21; 6853-6861.
5. Snyder GL, Keller RW, Zigmond MJ, (1990) Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J Pharmacol Exp Ther 253: 867-876.
6. Sarre S, Yuan H, Jonkers N, Van Hemelrijck A, Ebinger G, et al. (2004) In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J. Neurochem 90: 29-39.
7. Perez XA, Parameswaran N, Huang L, O'Leary KT, Quik M, (2008) Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates. J Neurochem 105: 1861-1872.
8. Bergstrom BP, Garris PA, (2003) "Passive stabilization" of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA -lesioned rat. J Neurochem 87: 1224-36.
9. Leng A, Mura A, Hengerer B, Feldon J, Ferger B, (2004) Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. Behav Brain Res 154: 375-383.
10. Salvatore MF, Fisher B, Surgener SP, Gerhardt GA, Rouault TA, (2005) Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2 (IRP-2) knockout mice. Mol Brain Res 139: 341-347.
11. Spielewoy C, Roubert C, Hamon M, Nosten-Bertrand M, Betancur C, et al. (2000) Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. 279-290.
12. Hebert MA, Gerhardt GA, (1998) Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in Fischer 344 rats. Brain Res 797: 42-54.
13. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, et al. (2007) Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 62: 468-475.
14. Madras BK, Fahey MA, Goulet M, Lin Z, Bendor J, et al. (2006) Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther 319: 570-585.
15. Miller GW, Abercrombie ED, (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72: 1516-1522.
16. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, et al. (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10: 631-634.
17. Nutt JG, Carter JH, Sexton GJ, (2004) The dopamine transporter: importance in Parkinson's disease. Ann Neurol 55: 766-773.
18. Pirker W, (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Movt Disord 18: S43-S51.
19. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT, (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22: 389-395.
20. Carboni E, Tanda GL, Frau R, Di Chiara G, (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55: 1067-1070.
21. Di Chiara G, Tanda GL, Frau R, Carboni E, (1992) Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. Neurochem Int Mar 20Suppl: 231S-235S.
22. Tanda G, Pontieri FE, Frau R, Di Chiara G, (1997) Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci 9: 2077-85.
23. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM, (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65: 111-116.
24. Yamamoto BK, Novotney S, (1998) Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 71: 274-280.
25. Wayment HK, Schenk JO, Sorg BA, (2001) Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J Neurosci 21: 35-44.
26. Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, et al. (2005) A modified MPTP treatment regime produces reporducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci 21: 841-54.
27. Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK, (2012) Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Neurobiol Dis 45: 1051-1067.
28. Hashimoto W, Kitayama S, Kumagai K, Morioka N, Morita K, et al. (2005) Transport of dopamine and levodopa and their interaction in COS-7 cells heterologously expressing monoamine neurotransmitter transporters and in monoaminergic cell lines PC12 and SK-N-SH. Life Sci 76: 1603-1612.
29. Arai A, Tomiyama M, Kannari K, Kimura T, Suzuki C, et al. (2008) Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse. 62: 632-635.
30. Paxinos G, Watson C (1998) Rat Brain in Stereotaxic Coordinates, 4th edition. Waltham, MA: Academic Press.
31. Hudson JL, Van Horne CG, Stromberg I, Brock S, Clayton J, et al. (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626: 167-174.
32. Salvatore MF, Apparsundaram S, Gerhardt GA, (2003) Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging 24: 1147-1154.
33. Salvatore MF, Pruett BS, Dempsey C, Fields V (2012) Comprehensive profiling of dopamine regulation in substantia nigra and ventral tegmental area. J. Vis. Exp. (66), e4171. doi:10.3791/4171.
34. Sabeti J, Gerhardt GA, Zahniser NR, (2002) Acute cocaine differentially alters accumbens and striatal dopamine clearance in low and high cocaine locomotor responders: Behavioral and electrochemical recordings in freely moving rats. J Pharmacol Exper Ther 302: 1201-1211.
35. Cragg SJ, Rice ME, Greenfield SA, (1997) Heterogeneity of electrically evoked dopamine release and reuptake in substantia nigra, ventral tegmental area, and striatum. J Neurophysiol 77: 863-873.
36. Hoffman AF, Lupica CR, Gerhardt GA, (1998) Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices. J Pharmacol Exp Ther 287: 487-496.
37. Chen BT, Rice ME, (2001) Novel Ca2+ dependence and time course of somatodendritic dopamine release: Substantia nigra versus striatum. J Neurosci 21: 7841-7847.
38. Keller CM, Salvatore MF, Pruett BS, Guerin GF, Goeders NE, (2011) Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat. Psychopharmacology 215: 513-526.
39. Snyder SH, Coyle JT, (1969) Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther 165: 78-86.
40. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, et al. (2008) Spared caudal brainstem SERT binding in early Parkinson's disease. J Cerebral Blood Flow & Metab. 28: 441-444.
41. Mura A, Jackson D, Manley MS, Young SJ, Groves PM, (1995) Aromatic l-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res 704: 51-60.
42. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, et al. (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parksinon's Disease. Ann Neurol 47: 493-503.
43. Bergstrom BP, Sanberg SG, Andersson M, Mithyantha J, Carroll FI, et al. (2011) Functional reorganization of the presynaptic dopaminergic terminal in parkinsonism. Neuroscience 193: 310-322.
44. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, et al. (2005) PET in LRRK2 mutations; comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128: 2777-2785.
45. Garris PA, Walker QD, Wightman RM, (1997) Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res 753: 225-234.
46. Sossi V, Dinelle K, Topping GJ, Holden JE, Doudet D, et al. (2009) Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J. Neurochem 109: 85-92.
47. Khakimova GR, Kozina EA, Sapronova AY, Ugryumov MV, (2010) Dopamine uptake in the substantia nigra and striatum in the presymptomatic and early symptomatic stages in Parkinsonian mice. Doklady Biological Sciences 435: 272-274.
48. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, et al. (1994) Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem. 269: 15985-15988.
49. Gu H, Wall SC, Rudnick G, (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269: 7124-7130.
50. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, et al. (1999) Characteristics of drug interactions with recombinant bio- genic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289: 877-885.
51. Pacholczyk T, Blakely RD, Amara SG, (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 350: 350-354.
52. Cragg SJ, Hille CJ, Greenfield SA, (2000) Dopamine release and uptake dynamics within nonhuman primate striatum in vitro. J Neurosci 20: 8209-8217.
53. Cass WA, Gerhardt GA, (1995) In vivo assessment of dopamine uptake in rat medial prefrontal cortex: comparison with dorsal striatum and nucleus accumbens. J Neurochem 65: 201-207.
54. Carboni E, Silvagni A, Vacca C, Di Chiara G, (2006) Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J Neurochem 96: 473-481.
55. Borgkvist A, Malmlöf T, Feltmann K, Lindskog M, Schilström B, (2011) Dopamine in the hippocampus is cleared by the norepinephrine transporter. Int J Neuropsychopharmacol Jun 14: 1-10.
56. Vizi ES, Zsilla G, Caron MG, Kiss JP, (2004) Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: implications for the action of selective serotonin reuptake inhibitors. J Neurosci 24: 7888-7894.
57. Larsen MB, Sonders MS, Mortensen OV, Larson GA, Zahniser NR, et al. (2011) Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation. J Neurosci 31: 6605-6615.
58. Kannari K, Shen H, Arai A, Tomiyama M, Baba M, (2006) Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett 402: 62-65.
59. Navailles S, Bioulac B, Gross C, De Deurwaerdere P, (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 38: 136-143.
60. Kerenyi L, Ricuarte GA, Schretlen DJ, McCann U, Varga J, et al. (2003) Position emission tomography of striatal serotonin transporters in Parkinson's disease. Arch. Neurol. 60: 1223-1229.
61. Engel K, Zhou M, Wang J, (2004) Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem. 279: 50042-50049.
62. Zhou M, Engel K, Wang J, (2007) Evidence for significant contribution of a newly identified monoamine transpoter (PMAT) to serotonin uptake in the human brain. Biochem Pharmacol 73: 147-154.
63. Engel K, Wang J, (2005) Interaction of organic cation with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68: 1397-1407.
64. Koepsell H, Lips K, Volk C, (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 24: 1227-1251.
65. Gasser PJ, Lowry CA, Orchinik M, (2006) Corticosterone-sensitive monoamine transport in the rat dorsolmedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci. 36: 8758-8766.
66. Gründemann D, Köster S, Kiefer N, Breidert T, Engelhardt M, et al. (1998) Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem 273: 30915-30920.
67. Teismann P, Schulz JB, (2004) Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res. 318: 149-161.
68. Takeda H, Inazu M, Matsumiya T, (2002) Astroglial dopamine transport is mediated by norepineprine transporter. Arch Pharmacol 366: 620-623.
69. Inazu M, Takeda H, Matsumiya T, (2003) Functional expression of the norepinephrine transporter in cultured rat astrocytes. J Neurochem 84: 136-144.
70. Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, et al. (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci USA. 106: 8043-8048.
71. Juorio AV, Li X-M, Walz W, Paterson IA, (1993) Decarboxylation of L-dopa by cultured mouse astrocytes. Brain Res 626: 306-309.
72. Tsai MJ, Lee EHY, (1996) Characterization of L-DOPA transport in cultured rat and mouse astrocytes. J Neurosci Res 43: 490-495.
73. Sandler M, (1971) How does L-DOPA work in Parkinsonism? The Lancet 17: 784.
74. Lloyd KG, Davidson L, Hornykiewicz O, (1975) The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195: 453-464.
75. Hornykiewicz O, Kish SJ (1986) Biochemical Pathophysiology of Parkinson's Disease. In: Yahr MD, Bergman KJ, editors. Advances in Neurology. New York: Raven Press. 19-34.
76. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, et al. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96: 1718-1727.
77. Cenci MA, (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30: 236-243.
78. Fisone G, Bezard E, (2011) Molecular mechanisms of L-DOPA-induced dyskinesia. Int Rev Neurobiol 98: 95-122.
79. Buck K, Ferger B, (2009) Comparison of intrastriatal administration of noradrenaline and L-DOPA on dyskinesia movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Neuroscience 159: 16-20.
80. Swant J, Goodwin JS, North A, Ali AA, Gamble-George J, et al. (2011) {alpha}-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J Biol Chem 286: 43933-43943.